| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 31, 2005
Revised on October 6, 2005
Accepted on November 10, 2005
From the Molecular Cardiology (Z.S., K.B., E.H., B.W., J.K., X.C., M.A., S.B., T.F., H.K.) and Molecular Oncology Research Institutes (P.N.T.), Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Mass; Vertex Pharmaceuticals, Inc (L.P., U.G., Y.-M.W., R.M., K.K., M.N., F.S., Y.m-Y.), Cambridge Mass; and Department of Biochemistry (W.m.H.), Tufts University, Boston, Mass.
* To whom correspondence should be addressed. E-mail: thomas.force{at}jefferson.edu.
Akt is a central regulator of cardiomyocyte survival after ischemic injury in vitro and in vivo, but the mechanisms regulating Akt activity in the postischemic cardiomyocyte are not known. Furthermore, although much is known about the detrimental role that the c-Jun N-terminal kinases (JNKs) play in promoting death of cells exposed to various stresses, little is known of the molecular mechanisms by which JNK activation can be protective. We report that JNKs are necessary for the reactivation of Akt after ischemic injury. We identified Thr450 of Akt as a residue that is phosphorylated by JNKs, and the phosphorylation status of Thr450 regulates reactivation of Akt after hypoxia, apparently by priming Akt for subsequent phosphorylation by PDK1. The reduction in Akt activity that is induced by JNK inhibition may have significant biological consequences, as we find that JNKs, acting via Akt, are critical determinants of survival in posthypoxic cardiomyocytes in culture. Furthermore, in contrast to selective p38-mitogen-activated protein kinase inhibition, which was cardioprotective in vivo, concurrent inhibition of both JNKs and p38-mitogen-activated protein kinases increased ischemia/reperfusion injury in the heart of the intact rat. These studies demonstrate that reactivation of Akt after resolution of hypoxia and ischemia is regulated by JNKs and suggest that this is likely a central mechanism of the myocyte protective effect of JNKs.
Related Article:
This article has been cited by other articles:
![]() |
E. Santamaria, M. I. Mora, C. Potel, J. Fernandez-Irigoyen, E. Carro-Roldan, R. Hernandez-Alcoceba, J. Prieto, A. L. Epstein, and F. J. Corrales Identification of Replication-competent HSV-1 Cgal+ Strain Signaling Targets in Human Hepatoma Cells by Functional Organelle Proteomics Mol. Cell. Proteomics, April 1, 2009; 8(4): 805 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Stathopoulou, I. Beis, and C. Gaitanaki MAPK signaling pathways are needed for survival of H9c2 cardiac myoblasts under extracellular alkalosis Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1319 - H1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Murphy and C. Steenbergen Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury Physiol Rev, April 1, 2008; 88(2): 581 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang Mitogen-Activated Protein Kinases in Heart Development and Diseases Circulation, September 18, 2007; 116(12): 1413 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fulop, Z. Zhang, R. B. Marchase, and J. C. Chatham Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2227 - H2236. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Milano, S. Morel, C. Bonny, M. Samaja, L. K. von Segesser, P. Nicod, and G. Vassalli A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1828 - H1835. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-X. Chen, H. Zeng, Q.-H. Tuo, H. Yu, B. Meyrick, and J. L. Aschner NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1664 - H1674. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guo, A. Sabri, H. Elouardighi, V. Rybin, and S. F. Steinberg {alpha}1-Adrenergic Receptors Activate AKT via a Pyk2/PDK-1 Pathway That Is Tonically Inhibited by Novel Protein Kinase C Isoforms in Cardiomyocytes Circ. Res., December 8, 2006; 99(12): 1367 - 1375. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bogoyevitch and B. Kobe Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases Microbiol. Mol. Biol. Rev., December 1, 2006; 70(4): 1061 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-C. Fan, Q. Yuan, G. Song, Y. Wang, G. Chen, J. Qian, X. Zhou, Y. J. Lee, M. Ashraf, and E. G. Kranias Small Heat-Shock Protein Hsp20 Attenuates {beta}-Agonist-Mediated Cardiac Remodeling Through Apoptosis Signal-Regulating Kinase 1 Circ. Res., November 24, 2006; 99(11): 1233 - 1242. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kerkela and T. Force p38 Mitogen-Activated Protein Kinase: A Future Target for Heart Failure Therapy? J. Am. Coll. Cardiol., August 1, 2006; 48(3): 556 - 558. [Full Text] [PDF] |
||||
![]() |
J. Shaw and L. A. Kirshenbaum Prime Time for JNK-Mediated Akt Reactivation in Hypoxia-Reoxygenation Circ. Res., January 6, 2006; 98(1): 7 - 9. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |